<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Abstract Background Despite improvements in medical care, patients with advanced" exact="cancer" post="still experience substantial symptom distress. There is increasing interest"/>
 <result pre="in the management of symptom burden in patients with advanced" exact="cancer" post="undergoing standard palliative care. Methods and design One hundred"/>
 <result pre="and acceptability of 1:1 THC/CBD for symptom relief in advanced" exact="cancer" post="patients. This study will allow the medical community to"/>
 <result pre="APP1152232 Background Despite improvements in medical care, patients with advanced" exact="cancer" post="still experience substantial symptom distress [1]. Palliative care aims"/>
 <result pre="nausea and vomiting (CINV), resistant epilepsy, pain and spasticity in" exact="multiple sclerosis," post="and symptoms associated with terminal illness [4]. Cannabis contains"/>
 <result pre="of some types of chronic pain, CINV and spasticity in" exact="multiple sclerosis" post="in some patients, with moderate evidence for sleep disorders"/>
 <result pre="meet the inclusion criteria will have an advanced histologically proven" exact="cancer" post="diagnosis (metastatic or locally advanced), be known to and"/>
 <result pre="opiates and â€˜other drugsâ€™. Exclusion criteria include a history of" exact="hypersensitivity" post="to any cannabinoid, unstable untreated cardiovascular disease, severe hepatic"/>
 <result pre="include a history of hypersensitivity to any cannabinoid, unstable untreated" exact="cardiovascular disease," post="severe hepatic impairment (total bilirubin â‰¥â€‰1.5 times the upper"/>
 <result pre="â‰¤â€‰20â€‰mL/min/1.73â€‰m2), a history of psychiatric disorders (severe depression or anxiety," exact="personality disorder," post="psychosis, schizophrenia, first-degree relative with schizophrenia and/or suicidal ideation),"/>
 <result pre="depression or anxiety, personality disorder, psychosis, schizophrenia, first-degree relative with" exact="schizophrenia" post="and/or suicidal ideation), cognitive impairment (St Louis University Mental"/>
 <result pre="It has been validated in the assessment of symptoms in" exact="cancer" post="patients [13]. Secondary outcomes include: Patient-determined effective dose of"/>
 <result pre="measure found valid for use in a wide variety of" exact="cancer" post="populations. To reduce patient burden, we will use the"/>
 <result pre="influence of potential covariates, for example age, sex, type of" exact="cancer" post="and disease severity, will be explored. This study is"/>
 <result pre="randomised trial to assess the efficacy of cannabinoids in advanced" exact="cancer" post="patients. A major strength of this study is that"/>
 <result pre="benefit in uncontrolled trials and high placebo response rates in" exact="cancer" post="pain trials [25, 26]. The trial design is pragmatic,"/>
 <result pre="Mental Status (SLUMS) Examination for detecting mild cognitive impairment and" exact="dementia" post="is more sensitive than the Mini-Mental Status Examination (MMSE)"/>
 <result pre="efficacy and toxicity of subcutaneous ketamine in the management of" exact="cancer" post="painJ Clin Oncol201230293611361710.1200/JCO.2012.42.108122965960"/>
</results>
